4
Changes in Ownership
Spyre Therapeutics, Inc. Filed Acc 0001758363-26-000002
Chief Executive Officer sold 15,000 shares at an average $30.68 ($460,134)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Turtle Cameron · Chief Executive Officer
Table I: Non-derivative
3 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-01-02 | Sale : show line 1 in the form 10b5-1 | −12,709 | $30.47 | $387,243 | 674,198 | D |
| 2026-01-02 | Sale : show line 2 in the form 10b5-1 | −2,191 | $31.79 | $69,652 | 672,007 | D |
| 2026-01-02 | Sale : show line 3 in the form 10b5-1 | −100 | $32.39 | $3,239 | 671,907 | D |
| Open-market sales · 15,000 sh · avg $30.68 · $460,134 | ||||||
Loading xslF345X05/wk-form4_1767753388.xml…